 SANTA MONICA, Calif., Dec. 14, 2020 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT today announced an additional commitment of up to 3.5 million from the Biomedical Advanced Research and Development Authority BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to 8.1 million. 